Factor Xa inhibitors: critical considerations for clinical development and testing

• Published in: Journal of thrombosis and thrombolysis Vol. 52; no. 2; pp. 397 - 402
• Main Author: Becker, Richard C.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2021; Springer Nature B.V
• Subjects: Anticoagulants; Anticoagulants - pharmacology; Anticoagulants - therapeutic use; Binding sites; Bioavailability; Biochemistry; Blood Coagulation - drug effects; Blood Coagulation Factors - pharmacology; Blood platelets; Cardiac arrhythmia; Cardiology; Cardiovascular disease; Coagulation; Cognition & reasoning; Collaboration; Disease prevention; Drug dosages; Drug interactions; Factor Xa - pharmacology; Factor Xa Inhibitors - pharmacology; Factor Xa Inhibitors - therapeutic use; FDA approval; Hematology; Humans; Inflammation; Leukocytes (mononuclear); Medicine; Medicine & Public Health; Patients; Physiology; Pulmonary embolisms; Thromboembolism; Thrombosis; Tissue factor; Factor X; Direct factor Xa inhibitors; Direct oral anticoagulants
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-021-02455-x

The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor bearing cells and the interface of coagulation proteins, platelets, mononuclear cells and the nuclear constituents of inflammatory cells. The goal for developing direct oral FXa inhibitors was to achieve rapid, selective, predictable, safe and effective anticoagulation across a broad group of patients expected to derive benefit. The history and development in patient care are exemplars of knowledge, translation and collaboration between the public and private sectors.